Target intelligence / Profile preview

RNA, U6 small nuclear 243, pseudogene (RNU6-243P)

Target
RNU6-243P
Molecular classification
Other, Pseudogene, Non-coding RNA
01

Overview

RNA, U6 small nuclear 243, pseudogene (RNU6-243P) is classified as a pseudogene belonging to the family of U6 small nuclear RNAs, but does not produce a functional product and is not recognized as a protein-coding gene or as a direct therapeutic target. Pseudogenes like RNU6-243P do not have established functional roles, disease associations, or relevance as drug targets or biomarkers in current biomedical research[1].

Other names
RNU6-243PRNA, U6 small nuclear 243, pseudogene

Beyond the preview

Go deeper on RNA, U6 small nuclear 243, pseudogene (RNU6-243P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 243, pseudogene (RNU6-243P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call